View on GitHub

In this release, we add two recent precision oncology approvals from the FDA.

Added entries:

  • (FDA) IDH1 p.R132C, p.R132G, p.R132H, p.R132L, and p.R132S and sensitivity to olutasidenib in acute myeloid leukemia.
  • (FDA) KRAS p.G12C and sensitivity to adagrasib in non-small cell lung cancer.